References

Allen WL, Johnston PG. Role of genomic markers in colorectal cancer treatment. J Clin Oncol. 2005;20:4545-4552.

Agafitei RD, Schneider S, Iqbal S, et al. Effect of celecoxib on neurotoxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin (CIFOX) [abstract]. J Clin Oncol. 2004;22(suppl):270s Abstract 3600.

Amador ML, Hidalgo M. Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer. Clin Colorectal Cancer. 2004;4:51-62.

American Academy of Family Physicians Practice Guidelines, 2005. Available at: http://www.aafp.org/afp/20050601/practice.html. Accessed July 20, 2005.

American Cancer Society. Cancer facts and figures 2006. Available at: http://www.cancer.org/docroot/stt/stt_0.asp. Accessed March 5, 2006.

American Cancer Society. Colorectal cancer facts and figures: special edition 2005. Available at: http://www.cancer.org/docroot/STT
/stt_0_2005.asp?sitearea=STT&level=1.

American Cancer Society. Guidelines for the early detection of cancer 2005. Available at: http://www.cancer.org/downloads/STT
/CPED2005v5PWSecured.pdf. Accessed July 20, 2005.

André T, Boni C. Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.

André T, de Gramont A. An overview of adjuvant systemic chemotherapy for colon cancer. Clin Colorectal Cancer. 2004;4(suppl 1):S22-S28.

André T, Figer A, Cervantes A, et al. FOLFOX7 compared to FOLFOX4: preliminary results of the randomized OPTIMOX study [abstract]. Proc Am Soc Clin Oncol. 2003;22:253. Abstract 1016.

Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60:6921-6926.

Arora A, Potter J. Older patients with colon cancer: is adjuvant chemotherapy safe and effective? J Am Geriatr Sac. 2003;51:567-569.

Avastin (bevacizumab) prescribing information. Available at: http://www.gene.com/gene/products/information/pdf/avastin-
prescribing.pdf. Accessed August 2, 2005.

Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891-899.

Benson AB III. Adjuvant chemotherapy of stage III colon cancer. Semin Oncol. 2005;32(6 suppI9):S74-S77.

Benson AB, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment–induced diarrhea. J Clin Oncol. 2004;22:2918-2926.

Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408-3419.

Berenson A. A cancer drug shows promise, at a price that many can’t pay. New York Times. February 15, 2006:A1, C2.

Bishop DT, Hall NR. The genetics of colorectal cancer. Eur J Cancer. 1994;30A:1946-1956.

Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485-493.

Bonosky K, Miller R. Hypersensitivity reactions to oxaliplatin: what nurses need to know. Clin J Oncol Nurs. 2005;9:325-330.

Brown KA, Esper P, Kelleher LO, O’Neill JEB, Polovich M, White JM, eds. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. Pittsburgh, Pa: Oncology Nursing Society; 2001.

Camptosar (irinotecan HCI for injection) prescribing information. Available at: http://www.pfizer.com/pfizer/download
/uspi_camptosar.pdf. Accessed August 2, 2005.

Cassidy J, Bjarnason GA, Hickish T, et al. Randomized double blind placebo controlled phase III study assessing the efficacy of xaliproden in reducing the cumulative peripheral sensory neuropathy induced by the oxaliplatin and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients with metastatic colorectal cancer [abstract]. J Clin Oncol. 2006;24(suppl, pt 1):147s. Abstract 3507.

Centers for Disease Control and Prevention. Colorectal cancer screening. Available at: http://www.cdc.gov/colorectalcancer
/basic_info/colorectal_cancer_screening.htm. Accessed March 15, 2006.

Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23:1803-1810.

Cohen SJ, Cohen RB, Meropol J. Targeting signal transduction pathways in colorectal cancer: more than skin deep. J Clin Oncol. 2005;23:5374-5385.

Colditz GA, Atwood KA, Emmons K, et al, for the Risk Index Working Group, Harvard Center for Cancer Prevention. Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index. Cancer Causes Control. 2000;11:477-488.

de Gramont A. Rapid evolution in colorectal cancer: therapy now and over the next five years. Oncologist. 2005;10(suppl 2):4-8.

de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years [abstract]. J Clin Oncol. 2005;23(suppl, pt 1):246s. Abstract 3501.

de Gramont A, Cervantes A, André T, et al. OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer [abstract]. J Clin Oncol. 2004;22(suppl):251s. Abstract 3525.

Delaunoit T, Goldberg RM, Sargent DJ, et al. Mortality associated with daily bolus 5-fluorouracil/LV administered in combination with either irinotecan or oxaliplatin. Cancer. 2004;101:2170-2176.

Dick SE, Crawford GH. Managing cutaneous side effects of epidermal growth factor receptor (HER1/EGFR) inhibitors. Community Oncol. 2005;2:492-496.

Dold F, Hoey D, Carberry M, et al. Hypersensitivity in patients with metastatic colorectal carcinoma undergoing chemotherapy with oxaliplatin [abstract]. Proc Am Soc Clin Oncol. 2002;21:370a. Abstract 1478.

Durand JP, Brezault C, Goldwasser F. Protection against oxaliplatin acute neurosensory toxicity by venlafaxine. Anticancer Drugs. 2003;14:423-425.

Erbitux (cetuximab) prescribing information. Available at: http://www.erbitux.com. Accessed August 8, 2006.

Ferro SA, Cosler LE, Wolff DA, et al. Variation in the cost of treatment for colorectal cancer. ASCO 2006 Gastrointestinal Cancers Symposium. Abstract 233. Available at: http://www.asco.org. Accessed August 8, 2006.

Figer A, Perez N, Carola E, et al. 5-Fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer [abstract]. J Clin Oncol. 2004;22(suppl):262s. Abstract 3571.

Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004;15:1330-1338.

Folprecht G, Rougier P, Saltz L, et al. Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer: meta-analysis of four trials investigating 5-FU and irinotecan [abstract]. J Clin Oncol. 2006;24(suppl, pt 1):165s. Abstract 3578.

Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004;10(pt 1):4055-4061.

Gasparini G, Longo R, Torino F, et al. Tailored therapy of colorectal cancer: results, challenges, and future directions. Cancer J. 2005;11:175-188.

Genzyme Genetics site. UGTlA1 molecular assay. Available at: http://www.genzymegenetics.com/testmenu/tests/cancer
/gene_p_testmenu_can_test_ugt1a1.asp. Accessed September 19, 2006.

Gobel BH. Chemotherapy-induced hypersensitivity reactions. Oncol Nurs Forum. 2005;32:1027-1035.

Gowda A, Goel R, Berdzik J, et al. Hypersensitivity reactions to oxaliplatin: incidence and management. Oncology (Williston Park). 2004;18:1671-1684.

Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;7:1209-1214.

Health Politics With Dr. Mike Magee. Colorectal cancer prevention: what are you waiting for? Available at: http://www.healthpolitics.org
/media/colorectal_cancer/slides_colorectal_cancer.pdf. Accessed July 26, 2005.

Hickish T, Boni C, Tabernero J,. et al. Oxaliplatin/5-fluorouracil/
leucovorin in stage II and III colon cancer: updated results of the international randomized “MOSAIC” trial. 2004 ASCO Gastrointestinal Cancers Symposium. Abstract 211. Available at: http://www.asco.org. Accessed July 21, 2005.

Hoff PM, Pazdur R. Progress in the development of novel treatments for colorectal cancer. Oncology (Williston Park). 2004;18:705-708.

Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med. 2003;348:879-880.

Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol. 2001;96:2992-3003.

Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol. 2005;20:4553-4559.

Krozely P. Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors. Clin J Oncol Nurs. 2004;8:163-168.

Land SR, Kopec J, Cecchini R, et al. Patient-reported neurotoxicity with FULV versus FLOX in patients with stage II or III carcinoma of the colon: results of the NSABP Protocol C-07 [abstract]. J Clin Oncol. 2006;24(suppl, pt 1):162s. Abstract 3564.

Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Clin Oncol. 2004;8(suppl 1):S31-S40.

Lindblom A. Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr Opin Oncol. 2001;13:63-69.

Maindrault-Goebel F, Lledo G, Chibaudel B, et al. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals after FOLFOX in patients with metastatic colorectal cancer: a GERCOR study [abstract]. J Clin Oncol. 2006;24(suppl, pt 1):147s. Abstract 3504.

Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352:476-487.

Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic colonography. Ann Intern Med. 2005;142:635-650.

National Cancer Institute Clinical Trials (PDQ) page. Protocol RP-64174-V-307 (PETACC-3). Phase III randomized study of adjuvant fluorouracil and leucovorin calcium with or without irinotecan in patients with resected stage III colorectal cancer. Available at: http://cancer.gov/clinicaltrials/RP-64174-V-307. Accessed March 3, 2005.

National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: http://ctep.cancer.gov/reporting
/ctc.html. Accessed August 8, 2006.

National Comprehensive Cancer Network. Clinical practice guidelines in oncology: colon cancer, v.2.2006. Available at: http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf. Accessed February 21, 2006.

National Comprehensive Cancer Network. Clinical practice guidelines in oncology: antiemesis, v.2.2006. Available at: http://www.nccn.org
/professionals/physician_gls/PDF/antiemesis.pdf. Accessed February 18, 2006.

National Comprehensive Cancer Network. Clinical practice guidelines in oncology: senior adult oncology, v.1.2005. Available at: http://www.nccn.org/professionals/physician_gls/PDF/senior.pdf. Accessed July 1, 2006.

Pederiva S, Caspar CB. Management of acute oxaliplatin-related peripheral sensory neuropathy with magnesium and calcium [abstract]. J Clin Oncol. 2004;22(suppl):297s. Abstract 3715.

Perez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor–associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005;10:345-356.

Perez-Soler R, Zou Y, Li T, et al. Topical vitamin K3 (vit K3, menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin [abstract]. J Clin Oncol. 2006;24(suppl, pt 1):129s. Abstract 3036.

Physicians Desk References, ed. 2006 Redbook: Pharmacy’s Fundamental Reference. Montvale, NJ: Thomson PDR; 2006.

Rakkar AS. Management of hypersensitivity reactions to oxaliplatin with SC epinephrine. 2006 ASCO Gastrointestinal Cancers Symposium. Abstract 258. Available at: http://www.asco.org. Accessed August 8, 2006.

Saif MW. Oral calcium ameliorating oxaliplatin-induced peripheral neuropathy. J Appl Res. 2004;4:576-582.

Saltz LB. Metastatic colorectal cancer: is there one standard approach? Oncology (Williston Park). 2005;19:1147-1160.

Saltz LB. Understanding and managing chemotherapy·induced diarrhea. J Support Oncol. 2003;1:35-46.

Saltz LB, Chung KY, Timoney J, et al. Simplification of bevacizumab administration: do we need 90, 60, or even 30 minute infusion times [abstract]? J Clin Oncol. 2006;24(suppl, pt 1):156s. Abstract 3542.

Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-1208.

Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883-890.

Sargent DJ, Goldberg RM, Bleiberg H, et al. A pooled safety and efficacy analysis of the FOLFOX4 regimen (bi-monthly oxaliplatin plus fluorouracil/leucovorin) in elderly compared to younger patients with colorectal cancer [abstract]. J Clin Oncol. 2006;24(suppl, pt 1):150s. Abstract 3517.

Sargent DJ. Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091-1097.

Sargent C, Murphy D. What you need to know about colorectal cancer. Nursing. 2003;33:36-41.

Schrag D. The price tag on progress: chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317-319.

Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425-1433.

Segnan N, Senore C, Andreoni B, et al, for the SCORE2 Working Group—Italy. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. J Natl Cancer Inst. 2005;97:347-357.

Skibber JM, Hoff PM, Minsky BD. Cancer of the colon. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer Principles & Practice of Oncology. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:1216-1271.

Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2005. CA Cancer J Clin. 2005;55:31-44.

Sorich J, Taubes B, Wagner A, Hochster H. Oxaliplatin: practical guidelines for administration. Clin J Oncol Nurs. 2004;8:251-256.

Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.

Tournigand C, Cervantes A, Figer A, et al. OPTIMOXl: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer. J Clin Oncol. 2006;24:394-400.

Twelves C, Wong A, Nowacki MP, et al. Capecetibine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696-2704.

US Food and Drug Administration. FDA clears genetic test that advances personalized medicine: test helps determine safety of drug therapy. Available at: http://www.fda.gov/bbs/topics/news/2005
/new01220.html. Accessed September 19, 2006.

US Food and Drug Administration, Center for Drug Evaluation and Research. Listing of approved oncology drugs with approved indications. Available at: http://www.fda.gov/cder/cancer
/druglistframe.htm. Accessed July 20, 2006.

US Preventive Services Task Force. Screening for colorectal cancer: recommendations and rationale. July 2002. Rockville, Md: Agency for Healthcare Research and Quality Available at: http://www.ahrq.gov
/clinic/3rduspstf/colorectal/colorr.htm. Accessed July 20, 2005.

Van Gerpen R. An overview of oral mucositis. Oncol Support Care Q. 2005;3(2):4-10.

Viale PH. Expanded treatment options in the adjuvant therapy of colon cancer: implications for oncology nurses. Oncol Nurs Forum. 2006;33:81-90.

Viale PH, Fung A, Zitella L. Advanced colorectal cancer: current treatment and nursing management with economic considerations. Clin J Oncol Nurs. 2005;9:541-552.

Viale PH, Mister S. Utilization of medication-assistance programs for medically uninsured patients: one public teaching hospital’s experience. Clin J Oncol Nurs. 2001;5:247-252.

Wilkes GM. New therapeutic options in colon cancer: focus on oxaliplatin. Clin J Oncol Nurs. 2002;6:131-137.

Wilkes GM. Therapeutic options in the management of colon cancer: 2005 update. Clin J Oncol Nurs. 2005;9:31-44.

Xeloda (capecitabine tablets) prescribing information. Available at: http://www.rocheusa.com/products/xeloda/pi.pdf. Accessed February 21, 2006.

Xiao H, Lichtman SM. Management of colorectal cancer in older patients. Oncology (Williston Park).. 2006;20:741-750.

Yamamoto DS, Viale PH, Zhao G. Severe acneiform rash. Clin J Oncol Nurs. 2004;8:654-656.

Zaniboni A, Labianca R. Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann Oncol. 2004;15:1310-1318.